Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Histrelin

    ACTIVE PHARMA INGREDIENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Myovant's oral prostate cancer drug matches incumbent in phase 3
    Myovant's oral prostate cancer drug matches incumbent in phase 3

    20 Nov 2019

    // N. P Taylor FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/myovant-s-oral-prostate-cancer-drug-matches-incumbent-phase-3

    N. P Taylor FIERCE BIOTECH
    20 Nov 2019
    Share Share
    Myovant's oral prostate cancer drug matches incumbent in phase 3
    Myovant's oral prostate cancer drug matches incumbent in phase 3

    20 Oct 2019

    // N. P Taylor FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/myovant-s-oral-prostate-cancer-drug-matches-incumbent-phase-3

    N. P Taylor FIERCE BIOTECH
    20 Oct 2019
    Share Share
    Myovant's oral prostate cancer drug matches incumbent in phase 3
    Myovant's oral prostate cancer drug matches incumbent in phase 3

    20 Oct 2019

    // N. P Taylor FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/myovant-s-oral-prostate-cancer-drug-matches-incumbent-phase-3

    N. P Taylor FIERCE BIOTECH
    20 Oct 2019
    Share Share